121 related articles for article (PubMed ID: 16461297)
1. Chronic myeloid leukemia in 2006: a perspective.
Mauro MJ; Deininger MW
Haematologica; 2006 Feb; 91(2):152. PubMed ID: 16461297
[No Abstract] [Full Text] [Related]
2. Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Mauro MJ
Haematologica; 2005 Mar; 90(3):291B. PubMed ID: 15749655
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
4. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
5. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
6. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D
Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054
[No Abstract] [Full Text] [Related]
7. Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
Thornley I; Perentesis JP; Davies SM; Smith FO; Champagne M; Lipton JM
Med Pediatr Oncol; 2003 Aug; 41(2):115-7. PubMed ID: 12825214
[No Abstract] [Full Text] [Related]
8. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
Wang L; Knight K; Lucas C; Clark RE
Haematologica; 2006 Feb; 91(2):235-9. PubMed ID: 16461309
[TBL] [Abstract][Full Text] [Related]
9. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
[No Abstract] [Full Text] [Related]
10. Optimizing therapy of chronic myeloid leukemia.
Deininger MW
Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
Calabrese G; Fantasia D; Di Gianfilippo R; Stuppia L; Di Lorenzo R; Palka G
Haematologica; 2006 Jul; 91(7):994-5. PubMed ID: 16818290
[TBL] [Abstract][Full Text] [Related]
12. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
Tamaki H; Ogawa H
Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
[No Abstract] [Full Text] [Related]
14. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
15. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
Nagai T
Rinsho Ketsueki; 2007 Oct; 48(10):1360-9. PubMed ID: 17933121
[No Abstract] [Full Text] [Related]
16. Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
Sausville EA
Clin Cancer Res; 2003 Apr; 9(4):1233-4. PubMed ID: 12684388
[No Abstract] [Full Text] [Related]
17. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
18. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
19. Autotransplantation for chronic myeloid leukemia: is it useful?
Olavarria E
Haematologica; 2002 Jan; 87(1):3-6. PubMed ID: 11801458
[No Abstract] [Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Xu LP; Huang XJ
Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
